RMC-6291

Revolution Medicines, Inc. · Phase 1 active Small molecule

At a glance

Generic name	RMC-6291
Sponsor	Revolution Medicines, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (PHASE1, PHASE2)
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RMC-6291 CI brief — competitive landscape report
RMC-6291 updates RSS · CI watch RSS
Revolution Medicines, Inc. portfolio CI